<DOC>
	<DOC>NCT00428610</DOC>
	<brief_summary>The primary objective is to determine whether LY573636 is effective in treating platinum-resistant ovarian cancer. Patients will receive an intravenous infusion of study drug once every 28 days. CT scans and CA-125 tests will be done before the first dose and then after every other treatment.</brief_summary>
	<brief_title>A Study of Chemotherapy Treatment for Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>Diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer At least 18 years old Have received at least one but no more than 2 systemic treatment regimens containing platinum (does not include regimens received before surgery for this cancer) Have platinumresistant disease Have received more than 2 systemic treatment regimens for platinumresistant disease Serious preexisting medical conditions Actively receiving warfarin (Coumadin) for treatment of venous thrombosis or other prothrombotic conditions</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>